RA/QA News Roll: Late October 2023
Here's what's happening at FDA and across the broader life science RA/QA space.
This is our biweekly recap of news and industry happenings curated for our paid subscribers. Our goal is to bring you the headline news and the stories, research, and insights that might be harder to find.
If you haven’t upgraded to a paid subscription yet, you can do so here.
Here are some key items from the past couple of weeks.
FDA Guidances and Related Documents
An updated guidance on Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities. This guidance document, originally implemented during the Covid-19 pandemic, has now undergone long-planned revisions.
A guidance document details FDA’s approach to regulating Non-Invasive Remote Monitoring Devices for Patient Monitoring. This policy was initially issued in draft form during the pandemic.
The FDA has submitted two pharmaceutical compounding guidance documents to the White House's Office of Information and Regulatory Affairs for review. These documents pertain to compounding practices involving bulk drug substances.
The FDA, along with Canadian and U.K. regulators, has released a new document outlining "guiding principles" for predetermined change control plans (PCCPs) concerning Machine Learning-Enabled Medical Devices.
FDA host a webinar on its proposed Laboratory Developed Test (LDT) rule today, Oct. 31. The hour-long webinar will feature a Q&A session “based on questions submitted prior to the webinar.” Questions will not be taken live.
Keep reading with a 7-day free trial
Subscribe to The FDA Group's Insider Newsletter to keep reading this post and get 7 days of free access to the full post archives.